By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
A medical device known as an intraocular lens (IOL) is used to replace the natural lens of the eye when it gets obscured as a result of ailments like cataracts or refractive problems. The lens is an essential component that focuses light onto the retina so that we may see crisp images. Vision is hampered when this lens becomes opaque or loses its transparency, and this is when an IOL is used.
In order to implant an IOL, the clouded natural lens must first be removed surgically using the phacoemulsification method, which entails shattering the lens into minuscule pieces using ultrasonic vibrations and then sucking it out. The IOL is gently put into the eye’s similar space after the natural lens has been removed.
IOLs are made from a variety of biocompatible substances that imitate the optical qualities of the natural lens, such as silicone or acrylic. IOLs come in a variety of types to meet the demands of every patient.
The clear vision offered by monogonal IOLs is typically for distant vision and is fixed at one specific distance. Contrarily, accommodating and multifocal IOLs provide a variety of focal points, permitting better vision at different distances and obviating the need for glasses or contact lenses. Astigmatism, a disorder brought on by an unnaturally shaped cornea, is corrected using tori IOLs.
The intraocular lens accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The first presbyopia-correcting intraocular lens (IOL) from Bausch + Lomb, a market leader in eye care and a fully owned division of Bausch Health Companies Inc., was introduced as Lux Smart, and its monogonal variant, Lux Good. Both come with Pure Refractive Optics (PRO) Technology and preloaded delivery systems.
As part of a whole line of cutting-edge IOLs, Lux Smart and Lux Good are made of a hydrophobic substance and represent the launch of a new platform for Bausch + Lomb. The monogonal and PC-IOL versions will be joined by a tori variant that uses the same platform. Bausch + Lomb continues to concentrate its efforts on delivering further premium IOLs and offering a full platform in response to a growing patient need in the premium market sector.
